## DOW: Dow Inc. - XLB: Basic Materials

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.8% in lower entry zone (4.0-10.0%), top quartile (88th pct) cross-sectional ranking. Short-term MRS_5 (1.7%) confirms momentum alignment. Strong momentum (+4.3% 5-day acceleration). Outperforming sector by 2.9%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($22.16)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Dow: sales share by region 2024**
- Source: Statista | 20251129T000815 | Neutral | Relevance: 99%
-  In 2024, the chemical company Dow generated the largest portion of its total revenue, 35.62%, in the United States. Following closely, Europe, the Middle East, Africa, and India accounted for 32.49% of sales, with the Rest of the World contributing 31.89%. This revenue breakdown offers insight into Dow's global market presence after its 2019 separation from DowDuPont into distinct entities focusing on commodity chemicals.

**2. Dow Inc. Shares: Can Cost-Cutting Fuel a Sustained Recovery?**
- Source: Ad-hoc-news.de | 20251201T072105 | Neutral | Relevance: 98%
- Dow Inc. is implementing a rigorous cost-reduction strategy, targeting $1 billion in savings by 2026, to combat high input costs and slow demand in the chemical sector. Market analysts are largely skeptical, with a consensus "Hold" rating and an average price target of $26.00, awaiting tangible proof that management can deliver on its promises to reverse the downward pressure on its stock. The company's cautious outlook for Q4 2025, anticipating only $725 million in EBITDA, underscores the challenges ahead as investors watch to see if these measures can lead to a sustained recovery.

**3. Johnson Fistel, PLLP Investigates Claims on Behalf of**
- Source: GlobeNewswire | 20251201T174200 | Neutral | Relevance: 98%
- Johnson Fistel, PLLP is investigating potential breach of fiduciary duty claims against officers and directors of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE). The investigations stem from alleged materially false and misleading statements, or failure to disclose material adverse facts, that led to investor losses. Shareholders who held shares continuously prior to specific dates are encouraged to contact the firm for potential corporate governance reforms and compensation.

**4. Dow Stock: Approaching A Bottom But Recovery Will Be Gradual (NYSE:DOW)**
- Source: Seeking Alpha | 20251129T230800 | Somewhat-Bullish | Relevance: 97%
- Shares of Dow have significantly underperformed due to weak demand and excess capacity in the chemicals sector, but there are signs that a bottom may be near due to ongoing plant closures and cost cuts. Despite negative free cash flow, Dow's strong cash position and disciplined cash management provide resilience. Patient investors may find a buying opportunity with an 18% total return potential as the company navigates a multi-year recovery.

**5. Europe Propylene Glycol Market Size, Share and Trends, 2033**
- Source: Market Data Forecast | 20251130T125114 | Somewhat-Bullish | Relevance: 86%
- The Europe propylene glycol market was valued at USD 983.06 million in 2024 and is projected to reach USD 1,656.64 million by 2033, growing at a CAGR of 5.97%. Key drivers include rising demand from pharmaceuticals and bio-based personal care products, while challenges include stringent regulations and volatility in feedstock pricing. Opportunities lie in expanding renewable propylene glycol production and its adoption in aviation de-icing fluids.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-19 | Citigroup | $23 | $25 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-19 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 9 ($0.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.4% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.9%)
- Blackrock Inc.: 7.0% (-4.3%)
- State Street Corpora: 4.8% (+5.5%)
- Pzena Investment Man: 3.8% (+0.3%)
- Geode Capital Manage: 2.6% (+1.7%)

### Key Risks

1. Long-term trend broken: trading 13.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.54 indicates undervaluation relative to growth. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $17.5B |
| Beta | 0.78 |
| 52W Range | $20.40 - $42.23 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.54 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from 0.4% to 4.8% (+4.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 at 1.7% confirms short-term momentum alignment. AM_20 at 5.9% shows strong absolute momentum above own 20MA. Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.79% (CS: 89) | Strong |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.057x | Above |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 0.862x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $23.84
- **Stop Loss:** $22.16 (7.0% risk)
- **Target:** $26.36 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 714
- **Position Value:** $17,021.76
- **Portfolio %:** 17.02%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

### Earnings

**Next:** 2026-01-29 (Est: $-0.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.30 | $-0.19 | +36.8% |
| 2025Q2 | $-0.16 | $-0.42 | -156.3% |
| 2025Q1 | $-0.01 | $0.02 | +249.8% |
| 2024Q4 | $0.24 | $0.00 | -100.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*